Barricaid Annular Closure Device
Intrinsic Therapeutics · Decision date Oct 9, 2025
What did the FDA approve?
FDA records P160050/S010 as a supplement to PMA P160050, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Oct 9, 2025.
FDA approval order statement
approval for a new 6mm baseplate sized implant.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Orthopedic
- Decision date
- Oct 9, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P160050/S010
- Regulatory pathway
- PMA supplement
- Applicant
- Intrinsic Therapeutics
- Product code
- QES
- Decision code
- APPR
- Decision date
- Oct 9, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Reherniation reduction device.
- Applicant
- Intrinsic Therapeutics
- Product code
- QES
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P160050/S010 received
Application receipt date recorded by FDA.
P160050/S010 · FDA decision
Normal 180 Day Track
P160050/S011 · Related supplement
Barricaid Annular Closure Device
P160050/S012 · Related supplement
Barricaid Annular Closure Device
Timeline entries are records held by MedtechLedger for P160050. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160050
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Barricaid Annular Closure DeviceP160050/S011 | Intrinsic Therapeutics | PMA supplement | Dec 18, 2025 | FDA |
Barricaid Annular Closure DeviceP160050/S012 | Intrinsic Therapeutics | PMA supplement | Mar 24, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Intrinsic Therapeutics
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 30 Commerce Way, Woburn, MA, 01801
Sources and methodology
- Original FDA record: P160050/S010
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
